SAGE to Present at the Piper Jaffray 27th Annual Healthcare Conference
November 24, 2015 16:05 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that it will present at the Piper Jaffray 27th Annual Healthcare Conference at 8:30...
SAGE Announces Third Quarter 2015 Financial Results and Recent Pipeline Progress
November 05, 2015 16:05 ET
|
SAGE Therapeutics
Expands Pipeline With Selection of Three Next Generation GABA and NMDA Modulators as Development Candidates Initiated Placebo-Controlled, Proof-of-Concept Trial of SAGE-547 in Severe Postpartum...
SAGE Announces Presentations at Upcoming November Investor Conferences
November 03, 2015 17:48 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that it will participate in three upcoming investor conferences in November: 24th Annual Credit...
SAGE to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015
October 29, 2015 16:10 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that the company will host a conference call and live webcast on Thursday, November 5, 2015 at...
SAGE to Present Data at Upcoming Scientific Conferences
October 08, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced upcoming data poster presentations at the 13th Annual Neurocritical Care Society Meeting, taking...
SAGE Announces Initiation of Phase 1 and First Dosing of SAGE-217
October 06, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced it has initiated dosing in a Phase 1 single ascending dose trial evaluating SAGE-217 in healthy...
SAGE Therapeutics to Participate in the 4th Annual Leerink Partners Rare Disease Roundtable
September 23, 2015 07:01 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
SAGE Therapeutics Expands Leadership Team With Key Appointments
September 21, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Sept. 21, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor
September 03, 2015 06:00 ET
|
SAGE Therapeutics
Clinically Meaningful Reduction of Tremor Amplitude Observed in Double-Blind, Placebo-Controlled Trial
Results Support Future Development of a Daily, Chronic, Oral Treatment
Study Represents...
SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
August 17, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Aug. 17, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE) today announced it has treated the first patient enrolled in the STATUS Trial (SAGE-547 Treatment as Adjunctive...